Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK
-
Published:2023-11-15
Issue:
Volume:7
Page:51
-
ISSN:2398-502X
-
Container-title:Wellcome Open Research
-
language:en
-
Short-container-title:Wellcome Open Res
Author:
Campbell CoriORCID, Wang TingyanORCID, Smith David A.ORCID, Freeman Oliver, Noble Theresa, Várnai Kinga AORCID, Harris SteveORCID, Salih HizniORCID, Roadknight GailORCID, Little Stephanie, Glampson Ben, Mercuri LucaORCID, Papadimitriou Dimitri, Jones Christopher R, Taylor Vince, Chaudhry Afzal, Phan Hang, Borca Florina, Olza JosuneORCID, Warricker Frazer, Romão LuisORCID, Ramlakhan David, English Louise, Klenerman Paul, Andersson Monique I.ORCID, Collier Jane, Nastouli Eleni, Khakoo Salim I., Gelson William, Cooke Graham S.ORCID, Woods Kerrie, Davies Jim, Barnes EleanorORCID, Matthews Philippa C.
Abstract
Background To determine the impact of the COVID-19 pandemic on the population with chronic Hepatitis B virus (HBV) infection under hospital follow-up in the UK, we quantified the coverage and frequency of measurements of biomarkers used for routine surveillance (alanine transferase [ALT] and HBV viral load). Methods We used anonymized electronic health record data from the National Institute for Health Research (NIHR) Health Informatics Collaborative (HIC) pipeline representing five UK National Health Service (NHS) Trusts. Results We report significant reductions in surveillance of both biomarkers during the pandemic compared to pre-COVID-19 years, both in terms of the proportion of patients who had ≥1 measurement annually, and the mean number of measurements per patient. Conclusions These results demonstrate the real-time utility of HIC data in monitoring health-care provision, and support interventions to provide catch-up services to minimise the impact of the pandemic. Further investigation is required to determine whether these disruptions will be associated with increased rates of adverse chronic HBV outcomes.
Funder
Wellcome Trust NIHR Oxford Biomedical Research Centre GlaxoSmithKline
Publisher
F1000 Research Ltd
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
|
|